Kargenera aim to increase liver cancer survival rate by 50%
Автор: UOS School of Healthcare Enterprise and Innovation
Загружено: 2025-11-21
Просмотров: 215
Liver cancer claims close to a million lives each year in the UK, and cases are rising fast. For patients who can’t undergo surgery, the prognosis is grim: less than two years to live, even with the best treatments available.
Kargenera is a University of Southampton spin out aiming to revolutionise cancer treatment through novel mRNA Immunotherapeutics. Co-founded by hepatologist Professor Salim Khakoo, based at University Hospital Southampton NHS Trust, and molecular biologist Professor Thejas Nagaraju, they are initially focusing on liver cancer, one of the UK’s most challenging cancers.
At the heart of their breakthrough is a powerful type of immune cell known as the natural killer (NK) cell, one of the body’s frontline defenders against cancer. NK cells are crucial components of the immune system that constantly monitor and destroy emerging cancer cells. Their ability to specifically target and destroy cancer cells makes them a promising avenue for effective cancer treatments.
Kargenera have developed a novel way to boost the cancer-fighting ability of these cells using mRNA technology, specifically targeting them against liver cancer with unprecedented precision.
Thanks to this precision medicine approach that differentiates their method from other immunotherapies, they hope to increase liver cancer survival by 50%.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
